Sign in

    Wayne Buchan

    Research Analyst at Cantor Fitzgerald

    Wayne Buchan serves as the Chief Risk Officer at Cantor Fitzgerald, specializing in risk management and oversight within the financial services industry. While previously referenced as a research analyst in some databases, his primary executive focus is not in equity research coverage, and there is no evidence he regularly covers or rates specific public companies or has a formal analyst performance track record with platforms such as TipRanks. Based in Clifton, New Jersey, Buchan assumed the Chief Risk Officer role after prior experience within Cantor Fitzgerald; information on his earlier career history, specific prior firms, or transition timeline is not publicly disclosed. Credentials such as securities licenses or FINRA registration and any notable industry recognitions or rankings are likewise not publicly documented.

    Wayne Buchan's questions to SCYNEXIS (SCYX) leadership

    Wayne Buchan's questions to SCYNEXIS (SCYX) leadership • Q1 2022

    Question

    On behalf of Louise Chen, Wayne Buchan from Cantor Fitzgerald asked about the competitive impact of Mycovia's recent approval, the nature of the relationship with the contract sales organization Amplity, and any existing distribution or market access challenges for BREXAFEMME.

    Answer

    President and CEO Dr. Marco Taglietti positioned BREXAFEMME as a unique, new class of drug with a favorable safety profile and an expected dual indication for treatment and prevention, differentiating it from competitors. He described the Amplity relationship as a flexible, fully dedicated sales force. Both Dr. Taglietti and Chief Commercial Officer Christine Coyne confirmed there were no significant distribution or market access issues, citing strong payer coverage and supply chain efficiency.

    Ask Fintool Equity Research AI